BioSante Pharmaceuticals Announces Presentation/Webcast at the BIO CEO & Investor Conference.LINCOLNSHIRE, Ill. -- BioSante Pharmaceuticals, Inc. (AMEX AMEX See: American Stock Exchange :BPA BPA British Paediatric Association. ) today announced that Stephen M. Simes, president and chief executive officer, will present at the 9th Annual BIO CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. & Investor Conference being held at the Waldorf-Astoria in New York, February 12-14, 2007. Mr. Simes' presentation will take place at 12:45 am EST EST electroshock therapy. EST abbr. electroshock therapy on February 14, 2007. The presentation will be webcast live and can be accessed by logging on to the investors section of BioSante Pharmaceuticals, Inc.'s website at http://www.biosantepharma.com on the day of the event. A replay of the presentation will also be available on the company's website. About BIO CEO Conference The 9th Annual BIO CEO & Investor Conference will provide a neutral forum where senior biotechnology executives, institutional investors, industry analysts, venture capitalists, investment bankers and other industry experts will have the opportunity to shape the future investment landscape of the biotechnology industry. Hosted by the Biotechnology Industry Organization Biotechnology Industry Organization or BIO was founded 1993 in Washington, DC. James C. Greenwood is BIO's current President. External links
About BioSante Pharmaceuticals, Inc. BioSante is developing a pipeline of hormone therapy products to treat both men and women. These hormone therapy products are gel formulations for transdermal administration that deliver bio-identical estradiol and testosterone. BioSante's lead products include Elestrin[TM] (estradiol gel), developed through FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approval by BioSante, indicated for the treatment of moderate-to-severe vasomotor vasomotor /vaso·mo·tor/ (-mo´tor) 1. affecting the caliber of blood vessels. 2. a vasomotor agent or nerve. va·so·mo·tor adj. symptoms associated with menopause, and LibiGel([R]) (transdermal testosterone gel), now in a Phase III clinical trial Noun 1. phase III clinical trial - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the , for the treatment of female sexual dysfunction (FSD). The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion. The transdermal gel formulations used in the women's gel products are licensed by BioSante from Antares Pharma. The company also is developing its calcium phosphate nanotechnology (CaP) for novel vaccines, including hepatitis B, avian flu and biodefense vaccines for toxins such as anthrax, as well as a system for delivering drugs via alternative routes of administration. Additional information is available online at: www.biosantepharma.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion